Tanxiu Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Tanxiu Chen has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
Wei Yan
2 shared publications- Wei Yan
Department of Thoracic Oncology, Jiangxi Cancer Hospital&Institute, Jiangxi Clinical Research Center for Cancer, The Second Affiliated Hospital of Nanchang Medical College, Jiangxi Key Laboratory of Oncology, Nanchang, China
2 shared publications - Anwen Liu
The Second Affiliated Hospital of Nanchang University 1 Department of Oncology Nanchang, PR China
1 shared publication Dan Xiao
Department of Thoracic Oncology, Jiangxi Cancer Hospital & Institute, Jiangxi Clinical Research Center for Cancer, Jiangxi Key Laboratory of Translational Research for Cancer, The Second Affiliated Hospital of Nanchang Medical College, Nanchang, Jiangxi, 330029, China
1 shared publicationDong Hong
Department of Thoracic Oncology, Jiangxi Cancer Hospital & Institute, Jiangxi Clinical Research Center for Cancer, Jiangxi Key Laboratory of Translational Research for Cancer, The Second Affiliated Hospital of Nanchang Medical College, Nanchang, Jiangxi, 330029, China
1 shared publicationHui Fu
Department of Pathology, Jiangxi Cancer Hospital, The Second Affiliated Hospital of Nanchang Medical College, Nanchang, China
1 shared publication
Latest Publications
- Open Access
- 2 December 2025
- Published by Elsevier in Experimental Cell Research
- Vol. 455 (1) , 114849
SLBP promotes lung adenocarcinoma progression by inhibiting ferroptosis and reprogramming glutamine metabolism via FADS2 interaction
- 2 December 2025
- Published by Elsevier in Experimental Cell Research
- Vol. 455 (1) , 114849
Open AccessSLBP promotes lung adenocarcinoma progression by inhibiting ferroptosis and reprogramming glutamine metabolism via FADS2 interaction
- Open Access
- 1 January 2025
- Published by SAGE Publications in Women's Health Reports
- Vol. 6 (1) , 681-690
Association Between Emphysema and Breast Cancer: Data from National Health and Nutrition Examination Survey (1998–2016)
Background: Emphysema has been linked to an elevated risk of lung cancer, yet the association between emphysema and breast cancer (BC) has not been established. Hence, our study aimed to investigate the potential correlation between emphysema as an exposure factor and BC as the outcome, while accounting for various covariates associated with BC. Methods: Participants from the National Health and Nutrition Examination Survey database from 1998 to 2016 were selected for analysis. Initially, ineligible individuals were excluded from this analysis. Subsequently, chi-square test and t -test were independently executed to assess variances in covariates and exposure factors between patients with BC and controls, leading to the development of a baseline table. Subsequently, weighted multivariate logistic regression analysis was conducted to explore the potential association between emphysema and BC, resulting in the development of three logistic regression models. Additionally, risk stratification analysis using weighted stratified logistic regression was performed to analyze the impact of emphysema on BC across different populations. Results: After excluding ineligible individuals, 4,937 participants remained, comprising 152 patients with BC and 4,785 controls. The baseline table revealed significant differences between BC and control samples in terms of emphysema ( p = 1 × 10 −2 ), age ( p = 5 × 10 −4 ), race ( p = 1 × 10 −3 ), marital status ( p = 5 × 10 −4 ), hypertension ( p = 5 × 10 −4 ), and number of pregnancies ( p = 2.1 × 10 −2 ). Furthermore, all p values for emphysema across the three model types were less than 0.05, indicating that the association between emphysema and BC was not significantly affected by other covariates. Meanwhile, the risk stratification analysis demonstrated that emphysema may be a risk factor for BC (odds ratio = 2.6, 95% confidence interval 1.25–5.41, p = 1.09 × 10 −2 ). Conclusion: The study’s findings indicating a correlation between emphysema and BC, with emphysema may be a risk factor for BC. This provides a potential theoretical basis for the development of BC treatment strategies.
- 1 January 2025
- Published by SAGE Publications in Women's Health Reports
- Vol. 6 (1) , 681-690
Open AccessAssociation Between Emphysema and Breast Cancer: Data from National Health and Nutrition Examination Survey (1998–2016)
Background: Emphysema has been linked to an elevated risk of lung cancer, yet the association between emphysema and breast cancer (BC) has not been established. Hence, our study aimed to investigate the potential correlation between emphysema as an exposure factor and BC as the outcome, while accounting for various covariates associated with BC. Methods: Participants from the National Health and Nutrition Examination Survey database from 1998 to 2016 were selected for analysis. Initially, ineligible individuals were excluded from this analysis. Subsequently, chi-square test and t -test were independently executed to assess variances in covariates and exposure factors between patients with BC and controls, leading to the development of a baseline table. Subsequently, weighted multivariate logistic regression analysis was conducted to explore the potential association between emphysema and BC, resulting in the development of three logistic regression models. Additionally, risk stratification analysis using weighted stratified logistic regression was performed to analyze the impact of emphysema on BC across different populations. Results: After excluding ineligible individuals, 4,937 participants remained, comprising 152 patients with BC and 4,785 controls. The baseline table revealed significant differences between BC and control samples in terms of emphysema ( p = 1 × 10 −2 ), age ( p = 5 × 10 −4 ), race ( p = 1 × 10 −3 ), marital status ( p = 5 × 10 −4 ), hypertension ( p = 5 × 10 −4 ), and number of pregnancies ( p = 2.1 × 10 −2 ). Furthermore, all p values for emphysema across the three model types were less than 0.05, indicating that the association between emphysema and BC was not significantly affected by other covariates. Meanwhile, the risk stratification analysis demonstrated that emphysema may be a risk factor for BC (odds ratio = 2.6, 95% confidence interval 1.25–5.41, p = 1.09 × 10 −2 ). Conclusion: The study’s findings indicating a correlation between emphysema and BC, with emphysema may be a risk factor for BC. This provides a potential theoretical basis for the development of BC treatment strategies.
- Open Access
- 1 March 2024
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 14, 1278245
Acute urinary retention due to corpus cavernosum penile metastasis from lung adenocarcinoma after targeted therapy: a case report and review of the literature
Background: Metastasis in penile corpus cavernosum from adenocarcinoma of lung is a rare but fatal disease, which was reported in cases without series studies. It causes various clinical symptoms seriously affecting the quality of life.Case presentation: A 72-year-old male smoker patient, who had a history of adenocarcinoma of lung after targeted therapy 36 months before, was admitted to Jiangxi Cancer Hospital because of presenting with aggressive dysuria and penis pain for one hour. A Foley catheter was inserted into the patient’s bladder with difficulty. Immediately do a bladder puncture. Emergency pelvic computed tomography (CT): a soft tissue nodule of 1.1 cm×1.4 cm was found in the cavernous area of the middle part of the penis, and the proximal urethra was dilated with a wide diameter of about 1.5 cm. The diagnosis of metastatic lung adenocarcinoma from the primary was made by CT-guided biopsy.Conclusion: The penis may be a site of metastasis from primary lung cancer, especially for old patient. Metastasis to the penis usually indicates that the primary lung cancer is at an advanced stage and the prognosis is very poor. More research is necessary to understand the underlying mechanism of adenocarcinoma of lung metastasis.
- 1 March 2024
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 14, 1278245
Open AccessAcute urinary retention due to corpus cavernosum penile metastasis from lung adenocarcinoma after targeted therapy: a case report and review of the literature
Background: Metastasis in penile corpus cavernosum from adenocarcinoma of lung is a rare but fatal disease, which was reported in cases without series studies. It causes various clinical symptoms seriously affecting the quality of life.Case presentation: A 72-year-old male smoker patient, who had a history of adenocarcinoma of lung after targeted therapy 36 months before, was admitted to Jiangxi Cancer Hospital because of presenting with aggressive dysuria and penis pain for one hour. A Foley catheter was inserted into the patient’s bladder with difficulty. Immediately do a bladder puncture. Emergency pelvic computed tomography (CT): a soft tissue nodule of 1.1 cm×1.4 cm was found in the cavernous area of the middle part of the penis, and the proximal urethra was dilated with a wide diameter of about 1.5 cm. The diagnosis of metastatic lung adenocarcinoma from the primary was made by CT-guided biopsy.Conclusion: The penis may be a site of metastasis from primary lung cancer, especially for old patient. Metastasis to the penis usually indicates that the primary lung cancer is at an advanced stage and the prognosis is very poor. More research is necessary to understand the underlying mechanism of adenocarcinoma of lung metastasis.
- Open Access
- 18 November 2019
- Published by Springer Nature in Journal of Ovarian Research
- Vol. 12 (1) , 1-11
S100A10 silencing suppresses proliferation, migration and invasion of ovarian cancer cells and enhances sensitivity to carboplatin
Background: Ovarian cancer is the leading cause of gynecological cancer-related mortality. The novel oncogene S100A10 has been reported to be involved in cancer cell proliferation, invasion and metastasis. The role of S100A10 in ovarian cancer has not been well studied and the effect of S100A10 on chemotherapy remains unclear. The aims of the present study were to investigate the functional role of S100A10 in the progression and carboplatin sensitivity of ovarian cancer. Methods: We examined the expression levels in tissues of S100A10 in 138 cases of ovarian cancer by IHC. To determine the functional roles of downregulated S100A10 in ovarian cancer, cell proliferation, colony formation, cell migration and invasion assays were performed. Chemoresistance was analyzed by apoptosis assay. A xenograft tumor model was established to confirm the role of S100A10 in carboplatin resistance in vivo. Using Western blot assays, we also explored the possible mechanisms of S100A10 in ovarian cancer. Results: The results showed that increased expression of S100A10 was positively associated with carboplatin resistance (P < 0.001), tumor grade (P = 0.048) and a poorer prognosis (P = 0.0053). Functional analyses demonstrated that S100A10 suppression significantly suppressed ovarian cancer cell proliferation, colony formation, cell migration and invasion, remarkably increased carboplatin-induced apoptosis in SKOV3 and A2780 cells and inhibited tumor growth in vivo. Downregulation of S100A10 expression could inhibit cell proliferation and enhance ovarian cancer cell sensitivity to carboplatin, possibly involving the regulation of cleaved-Caspase3 and cleaved-PARP. Conclusions: Together, the results of the present study reveal that S100A10 expression can be used as a predictive marker for the prognosis of ovarian cancer and chemosensitivity to carboplatin.
- 18 November 2019
- Published by Springer Nature in Journal of Ovarian Research
- Vol. 12 (1) , 1-11
Open AccessS100A10 silencing suppresses proliferation, migration and invasion of ovarian cancer cells and enhances sensitivity to carboplatin
Background: Ovarian cancer is the leading cause of gynecological cancer-related mortality. The novel oncogene S100A10 has been reported to be involved in cancer cell proliferation, invasion and metastasis. The role of S100A10 in ovarian cancer has not been well studied and the effect of S100A10 on chemotherapy remains unclear. The aims of the present study were to investigate the functional role of S100A10 in the progression and carboplatin sensitivity of ovarian cancer. Methods: We examined the expression levels in tissues of S100A10 in 138 cases of ovarian cancer by IHC. To determine the functional roles of downregulated S100A10 in ovarian cancer, cell proliferation, colony formation, cell migration and invasion assays were performed. Chemoresistance was analyzed by apoptosis assay. A xenograft tumor model was established to confirm the role of S100A10 in carboplatin resistance in vivo. Using Western blot assays, we also explored the possible mechanisms of S100A10 in ovarian cancer. Results: The results showed that increased expression of S100A10 was positively associated with carboplatin resistance (P < 0.001), tumor grade (P = 0.048) and a poorer prognosis (P = 0.0053). Functional analyses demonstrated that S100A10 suppression significantly suppressed ovarian cancer cell proliferation, colony formation, cell migration and invasion, remarkably increased carboplatin-induced apoptosis in SKOV3 and A2780 cells and inhibited tumor growth in vivo. Downregulation of S100A10 expression could inhibit cell proliferation and enhance ovarian cancer cell sensitivity to carboplatin, possibly involving the regulation of cleaved-Caspase3 and cleaved-PARP. Conclusions: Together, the results of the present study reveal that S100A10 expression can be used as a predictive marker for the prognosis of ovarian cancer and chemosensitivity to carboplatin.